Improved neurocognitive functions correlate with reduced inflammatory burden in atrial fibrillation patients treated with intensive cholesterol lowering therapy

Knut Tore Lappegård, Monica Pop-Purceleanu, Waander van Heerde, Joe Sexton, Indira Tendolkar, Gheorghe Pop, Knut Tore Lappegård, Monica Pop-Purceleanu, Waander van Heerde, Joe Sexton, Indira Tendolkar, Gheorghe Pop

Abstract

Background: Atrial fibrillation (AF) is associated with increased mortality and morbidity, including risk for cerebral macro- and microinfarctions and cognitive decline, even in the presence of adequate oral anticoagulation. AF is strongly related to increased inflammatory activity whereby anti-inflammatory agents can reduce the risk of new or recurrent AF. However, it is not known whether anti-inflammatory therapy can also modify the deterioration of neurocognitive function in older patients with AF. In the present study, older patients with AF were treated with intensive lipid-lowering therapy with atorvastatin 40 mg and ezetimibe 10 mg, or placebo. We examined the relationship between neurocognitive functions and inflammatory burden.

Findings: Analysis of inflammatory markers revealed significant reductions in high sensitivity C-reactive protein (hs-CRP), fibroblast growth factor (FGF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-1 receptor antagonist (IL-1RA), interleukin (IL)-9, IL-13 and IL-17, and interferon-γ (IFNγ) in the treatment group compared to placebo. Reduction in plasma concentration of IL-1RA, IL-2, IL-9 and IL-12, and macrophage inflammatory protein-1β (MIP-1β) correlated significantly with improvement in the neurocognitive functions memory and speed. Loss of volume in amygdala and hippocampus, as determined by magnetic resonance imaging (MRI), was reduced in the treatment arm, statistically significant for left amygdala.

Conclusions: Anti-inflammatory therapy through intensive lipid-lowering treatment with atorvastatin 40 mg and ezetimibe 10 mg can modify the deterioration of neurocognitive function, and the loss of volume in certain cerebral areas in older patients with AF. TRIAL REGISTRATION ClinicalTrials.gov: NCT00449410.

References

    1. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am CollCardiol. 2012;60:2263–2270. doi: 10.1016/j.jacc.2012.04.063.
    1. Lappegård KT, Hovland A, Pop GAM, Mollnes TE. Atrial fibrillation - inflammation in disguise? Scand J Immunol. 2013.
    1. Calò L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E, Meo A, Pandozi C, Staibano M, Santini M. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled tria. J Am CollCardiol. 2005;45:1723–1728. doi: 10.1016/j.jacc.2005.02.079.
    1. Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am CollCardiol. 2008;51:828–835. doi: 10.1016/j.jacc.2007.09.063.
    1. Liakopoulos OJ, Choi YH, Haldenwang PL, Strauch J, Wittwer T, Dörge H, Stamm C, Wassmer G, Wahlers T. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients. Eur Heart J. 2008;29:1548–1559. doi: 10.1093/eurheartj/ehn198.
    1. Rubens FD, Nathan H, Labow R, Williams KS, Wozny D, Karsh J, Ruel M, Mesana T. Effects of methylprednisolone and a biocompatible copolymer circuit on blood activation during cardiopulmonary bypass. Ann ThoracSurg. 2005;79:655–665. doi: 10.1016/j.athoracsur.2004.07.044.
    1. Healey JS, Morillo CA, Connolly SJ. Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling. Current Opinion in Cardiology. 2005;20:31–37.
    1. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the losartan intervention for End point reduction in hypertension (LIFE) study. J Am CollCardiol. 2005;45:712–719. doi: 10.1016/j.jacc.2004.10.068.
    1. Zhang G, Li J, Purkayastha S, Tang Y, Zhang H, Yin Y, Li B, Liu G, Cai D. Hypothalamic programming of systemic ageing involving IKK-β, NF-κB and GnRH. Nature. 2013;497:211–216. doi: 10.1038/nature12143.
    1. Gabuzda D, Yankner BA. Physiology: Inflammation links ageing to the brain. Nature. 2013;497:197–198. doi: 10.1038/nature12100.
    1. Ball J, Carrington MJ, Stewart S. SAFETY investigators. Mild cognitive impairment in high-risk patients with chronic atrial fibrillation: a forgotten component of clinical management? Heart. 2013;99:542–547. doi: 10.1136/heartjnl-2012-303182.
    1. Kilander L, Andrén B, Nyman H, Lind L, Boberg M, Lithell H. Atrial fibrillation is an independent determinant of low cognitive function: a cross-sectional study in elderly men. Stroke. 1998;29:1816–1820. doi: 10.1161/01.STR.29.9.1816.
    1. Miyasaka Y, Barnes ME, Petersen RC, Cha SS, Bailey KR, Gersh BJ, Casaclang-Verzosa G, Abhayaratna WP, Seward JB, Iwasaka T, Tsang TS. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. Eur Heart J. 2007;28:1962–1967. doi: 10.1093/eurheartj/ehm012.
    1. O'Connell E, Gray S, French M, Robertson H. Atrial fibrillation and cognitive function: case–control study. J NeurolNeurosurg Psychiatry. 1998;65:386–389. doi: 10.1136/jnnp.65.3.386.
    1. Ott A, Breteler M, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study: the Rotterdam Study. Stroke. 1997;28:316–321. doi: 10.1161/01.STR.28.2.316.
    1. Sabatini T, Frisoni GB, Barbisoni P, Bellelli G, Rozzini R, Trabucchi M. Atrial fibrillation and cognitive disorders in older people. J Am Geriatr Soc. 2000;48:387–390.
    1. Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, Casadei V, Grimaldi LME. Increased plasma levels of interleukin-1, interleukin-6 and a-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? Journal of Neuroimmunol. 2000;103:97–102. doi: 10.1016/S0165-5728(99)00226-X.
    1. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13:34–45.
    1. Gao SP, Deng XT, Ge LJ, Luan H, Zheng JG, Chen C, Jiang MH, Pan M. Is inflammation linked to thrombogenesis in atrial fibrillation? Int J Cardiol. 2011;149:260–261. doi: 10.1016/j.ijcard.2011.02.046.
    1. Van Kuilenburg J, Lappegård KT, Sexton J, Plesiewicz I, Lap P, Bouwels L, Sprong T, Mollnes TE, Verheugt F, Van Heerde WL, Pop GA. Persisting thrombin activity in elderly patients with atrial fibrillation on oral anticoagulation is decreased by anti-inflammatory therapy with intensive cholesterol-lowering treatment. J ClinLipidol. 2011;5:273–280.
    1. Tendolkar I, Enajat M, Zwiers MP, van Wingen G, de Leeuw FE, van Kuilenburg J, Bouwels L, Pop G, Pop-Purceleanu M. One-year cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke-free elderly with atrial fibrillation: evidence from a parallel group randomized trial. Int J Geriatr Psychiatry. 2012;27:49–58. doi: 10.1002/gps.2688.
    1. Mollnes TE, Brekke OL, Fung M, Fure H, Christiansen D, Bergseth G, Videm V, Lappegard KT, Kohl J, Lambris JD. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood. 2002;100:1869–1877.
    1. van Geffen M, van Heerde WL. Global haemostasis assays, from bench to bedside. Thromb Res. 2012;129:681–687. doi: 10.1016/j.thromres.2011.12.006.
    1. Loughin TM. A systematic comparison of methods for combining p-values from independent tests. Computational Statistics and Data Analysis. 2004;47:467–485. doi: 10.1016/j.csda.2003.11.020.
    1. Pesarin F. Multivariate Permutation Tests, with applications in biostatistics. Chichester: John Wiley & Sons; 2001.
    1. Kwok CS, Loke YK, Hale R, Potter JF, Myint PK. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology. 2011;76:914–922. doi: 10.1212/WNL.0b013e31820f2e38.
    1. Becker RC. Biomarkers in atrial fibrillation: investigating biologic plausibility, cause, and effect. J Thromb Thrombolysis. 2005;19:71–75. doi: 10.1007/s11239-005-0943-3.
    1. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J. 2006;27:136–149.
    1. Amar D, Zhang H, Heerdt PM, Park B, Fleisher M, Thaler HT. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest. 2005;128:3421–3427. doi: 10.1378/chest.128.5.3421.
    1. Carnes A, Chung K, Nakayama T, Nakayama H, Baliga S, Piao S, Kanderian A, Pavia S, Hamlin L, McCarthy M, Bauer A, Van Wagoner R. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res. 2001;89:e32–e38. doi: 10.1161/hh1801.097644.
    1. Imazio M, Brucato A, Ferrazzi P, Rovere ME, Gandino A, Cemin R, Ferrua S, Belli R, Maestroni S, Simon C, Zingarelli E, Barosi A, Sansone F, Patrini D, Vitali E, Trinchero R, Spodick DH, Adler Y. COPPS Investigators. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation. 2011;124:2290–2295. doi: 10.1161/CIRCULATIONAHA.111.026153.
    1. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J. 2004;25:1100–1107. doi: 10.1016/j.ehj.2004.04.025.
    1. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol. 2003;92:1343–1345. doi: 10.1016/j.amjcard.2003.08.023.
    1. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD. de Groot E;ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431–1443. doi: 10.1056/NEJMoa0800742.
    1. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207. doi: 10.1056/NEJMoa0807646.
    1. Rizos I, Tsiodras S, Rigopoulos AG, Dragomanovits S, Kalogeropoulos AS, Papathanasiou S, Sakadakis EA, Kremastinos DT. Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome. Cytokine. 2007;40:157–164. doi: 10.1016/j.cyto.2007.08.013.
    1. Ribeiro LR, Della-Pace ID, de Ferreira APO, Funck VR, Pinton S, Bobinski F, de Oliveira CV, Fiorin FDS, Duarte MMMF, Furian AF. Chronic administration of methylmalonate on young rats alters neuroinflammatory markers and spatial memory: Methylmalonate induces neuroinflammation in rats. Immunobiology. 2013.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться